



AWTTC

All Wales Therapeutics & Toxicology Centre
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfan

Medicines Access in Wales


Helen Adams



Grŵp Strategaeth Meddyginiaethau Cymru Gyfan
All Wales Medicines Strategy Group



Access routes available



AWTTC



Grŵp Strategaeth Meddyginiaethau Cymru Gyfan
All Wales Medicines Strategy Group

What are the challenges?

Responding to changes happening at national and international level

Monitoring NICE appraisals in the work programme to inform the health boards/trusts about medicines being approved

Engagement with pharmaceutical industry to ensure Wales is ready to adopt NICE guidance at FAD publication (i.e. commercial arrangements and service requirements)

Review of medicines not on NICE work programme so that advice is available in Wales where it is clinically needed.



AWTTC



Grŵp Strategaeth Meddyginiaethau Cymru Gyfan
All Wales Medicines Strategy Group

How are we responding?



National and international collaboration



Adapting the horizon scanning process



Reviewing our processes for identifying medicines which may require AWMMSG advice (inclusion criteria/scrutiny panel)




Review of the remit of the AWMMSG sub-committees




Adaptation of the current assessment processes through AWMMSG



CURRENT MEDICINES ACCESS IN WALES




PROPOSED MEDICINES ASSESSMENT ROUTES IN WALES



AWMSG MEDICINES ASSESSMENT ROUTES FOR UNLICENSED MEDICINES

- The medicine is not licensed for the indication of interest
- There is a clearly defined and specific cohort of patients identified by NHS Wales
- The requested use of the medicine is outside of an accepted treatment pathway, i.e. the specific sequence of treatment/s has not been approved by NICE/AWMSG
- There is no routinely available licensed medicine that will meet the patient's needs
- Requests for consideration of medicines are through the service in NHS Wales
- Opportunity for company to provide a commercial discount and comment on evidence report



- All recommendations are interim and subject to review (12 months after initial decision then every 1-3 years)
- Health boards are responsible for implementation of One Wales decisions
- Clinicians are required to collect and report patient outcomes
- If the product becomes licensed for the indication it will no longer be suitable for this process and the company will be expected to submit for HTA

AWMSG MEDICINES ASSESSMENT ROUTES FOR LICENSED MEDICINES

- New licensed medicine
- Significant licence extension
- Likely to have a significant impact in NHS Wales (service and/or budget)
- Delay in NICE advice or NICE advice not applicable due to associated commercial arrangement

Licensed
Medicines

- Not selected by NICE topic selection
- No significant cost/impact to NHS Wales
- Included in national guidelines
- National commissioning available elsewhere in UK

Full
assessment

Limited
assessment

Ongoing work.....



Engage with health care professionals to identify medicines where there is a clinical need for advice



Engage with pharmaceutical industry to gather information on pipeline medicines



Engage with NICE/NHSE to identify gaps in advice in NHS Wales



Collaborate with medicines value unit to ensure a coordinated approach



AWTTC



Grŵp Strategaeth Meddyginiaethau Cymru Gyfan
All Wales Medicines Strategy Group

Medicines ecosystem



Diolch yn fawr Thank you

<https://awttc.nhs.wales>

<https://cttcg.gig.cymru>

[@AWTTCcomms](#)

[@AWTTCcymraeg](#)



@AWTTC - All Wales Therapeutics & Toxicology Centre



AWTTC



Grŵp Strategaeth Meddyginiaethau Cymru Gyfan
All Wales Medicines Strategy Group